InvestorsHub Logo
Followers 9
Posts 750
Boards Moderated 0
Alias Born 10/19/2008

Re: None

Sunday, 03/02/2014 12:38:01 PM

Sunday, March 02, 2014 12:38:01 PM

Post# of 146235
Quote - 'The recent addition of the company's DengueCide for dengue fever to the list of the FDA's orphan drugs could possibly give NanoViricides a corner on the market. The treatment showed an unprecedented 50% survival rate in animal trials. When left untreated, dengue fever has 100% fatality, and there are only a few drugs in the clinical stage, including balapiravir from Roche'

Read more: Virus-killing nanoviricides win orphan status for dengue fever - FierceDrugDelivery http://www.fiercedrugdelivery.com/story/virus-killing-nanoviricides-win-orphan-status-dengue-fever/2013-08-14#ixzz2upOQEykY

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News